Individualizing AR Pathway Inhibitor Selection in Metastatic Castration Sensitive Prostate Cancer (mCSPC)

In this segment, Dr. Charles J. Ryan leads a panel discussion with Dr. Alan H. Bryce, Dr. Murilo De Almeida Luz, and Dr. Jayram on key clinical considerations that influence treatment selection when intensifying therapy for metastatic castration sensitive prostate cancer (mCSPC). The panel discusses how cardiovascular risk, metabolic complications, and steroid exposure can affect both treatment choice and long term monitoring strategies. The physicians emphasize that many patients with mCSPC have underlying comorbidities that must be carefully evaluated before initiating combination therapy. The conversation also reviews long term efficacy and safety data from clinical trials evaluating androgen receptor pathway inhibitors in metastatic hormone sensitive prostate cancer, highlighting how these findings guide real world practice. The panel underscores the importance of tailoring treatment decisions based on individual patient characteristics, including age, comorbidity burden, and functional status. Overall, the discussion illustrates how clinicians personalize therapy to balance efficacy, safety, and long term tolerability in metastatic castration sensitive prostate cancer.